- Life Sciences
Neural Analytics offers a non-invasive solution for measuring a critical physiologic parameter that currently requires a neurosurgeon to drill a hole in the patient’s skull. Our device, RapidICP, has a patented method to noninvasively measure intracranial pressure (ICP) using a portable, inexpensive ultrasound device that can be used by a trained technician.
No clinically accepted medical device exists for noninvasive ICP assessment. As a consequence, the practice of ICP assessment has been limited to brain injury patients in neurocritical care units. Intracranial hypertension (IH, increased ICP) is a life-threatening condition in severe traumatic brain injury (TBI), and it has been shown that ICP monitoring significantly reduces mortality rates in this patient population. There are approximately 300,000 severe TBI annually in the United States, resulting in over 50,000 deaths; however, 40% of these patients do not receive the recommended monitoring as the cost and expertise required for ICP monitor placement is a substantial barrier for many rural and community hospitals.
Although there is an obvious unmet need, previous attempts have failed to produce a clinically accepted device. With nearly ten years of academic development and funding through NIH grants, our group has developed a promising new algorithm to expand the use of the well-established ultrasound technique known as Transcranial Doppler (TCD) to noninvasively diagnose IH. Our technology, RapidICP, is based on recognition of distinct patterns in the pulsatile cerebral blood flow velocity (CBFV) signals that are associated with IH. Our initial results involving about 100 patients show an accuracy of 92% for detecting IH. In summary, our technology consists of the patented pattern recognition algorithm and the large signal repository of CBFV and invasive ICP signals for algorithm improvement and validation, allowing for a noninvasive alternative to IH detection.
Neural Analytics has assembled a diverse team with complementary skills and backgrounds to commercialize this technology. The technical lead on this project is Robert Hamilton, a fifth-year PhD candidate in Biomedical Engineering at UCLA who has spent the past four years refining and developing this technology within an academic setting. The business aspects of the venture will be overseen by Dr. Leo Petrossian; a repeat entrepreneur and first year UCLA Anderson MBA student, Dr. Petrossian has five years of experience developing technologies and businesses within the biotech space. Leading the business development aspects of the venture is Dan Hanchey; Mr. Hanchey is a third-year MBA candidate at UCLA Anderson who has 16 years of experience developing manufacturing automation software. Acting as advisors to the team are Xiao Hu Ph.D. and Neil Martin M.D. Dr. Xiao Hu, Mr. Hamilton’s graduate advisor and co-inventor of the technology will be advising the team on the technical development. Finally, Dr. Neil Martin, the Chief of Neurosurgery at UCLA, will be severing as the medical advisor for the team.
Investor questions have not yet been answered for this business